Therapeutic use of apohemoglobin-haptoglobin complexes to treat hemolysis and as a drug carrier for targeting CD163+ macrophages and monocytes
TS-075261 — Problem
Hemolysis, the process by which the red blood cell membrane ruptures, releasing hemoglobin (Hb), is typically managed in mammalian organisms by intrinsic proteins such as hemopexin (Hpx) and haptoglobin (Hp). However, their concentrations in plasma are very limited, so, in conditions with s…
- College: College of Engineering (COE)
- Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
- Licensing Officer: Schworer, Adam
Precision peptide therapy for cardiac ryanopathies
TS-075234 — PROBLEM
Dysregulation of the cardiac ryanodine receptor (RyR2) leads to abnormal Ca2+ release, a central driver of serious cardiovascular diseases including congestive heart failure (CHF), catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmogenic right ventricular dysplasia (ARVD…
- College: College of Medicine (COM)
- Inventors: Singh, Harpreet
- Licensing Officer: Willson, Christopher
Cyclic Cell-Penetrating Peptides: Revolutionizing Intracellular Delivery
TS-073895 — The Need
In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Cell-penetrating peptides (CPPs) initially were considered a potential solution. Short sequences of amino acid…
- College: College of Arts and Sciences (ASC)
- Inventors: Pei, Dehua
- Licensing Officer: Dahlman, Jason "Jay"
Breakthrough In Delivery: Expanding Access to Intracellular Targets for Next-Generation Therapies
TS-072004 — Empower your pipeline with a versatile platform for efficient
, customizable biomolecule transport.
Overview
Intracellular delivery remains a persistent challenge in drug delivery, gene editing, and biotechnology. Pharmaceutical and biotech companies lose valuable opportunities when promising drugs and biologics cannot reach their intended targets inside cells, limiting product effectiveness and m…
- College: College of Arts and Sciences (ASC)
- Inventors: Bong, Dennis
- Licensing Officer: Panic, Ana
Revolutionizing Corneal Repair: Advanced MG53-Based Treatment for Enhanced Ocular Health
TS-066878 — New and more effective treatments for corneal injuries.
Current treatments for corneal injuries often have side effects that can compromise vision, highlighting the need for a new method that enhances ocular tissue repair without such drawbacks.
The Need
Injuries to the cornea can lead to severe pain, infection, and vision loss due to scarring and abno…
- College: College of Optometry
- Inventors: Chandler, Heather; Ma, Jianjie; Tan, Tao; Zhu, Hua
- Licensing Officer: Schultz, Teri
Cyclic Cell-Penetrating Peptides: Revolutionizing Intracellular Delivery
TS-066751 — The Need
In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Cell-penetrating peptides (CPPs) initially were considered a potential solution. Short sequences of amino acid…
- College: College of Arts and Sciences (ASC)
- Inventors: Pei, Dehua
- Licensing Officer: Dahlman, Jason "Jay"
MG53: Enhancing Tissue Performance and Repairing Damaged Tissue
TS-066191 —
, T2019-164
, T2020-002
, T2020-159
, T2020-222: Using rhMG53 to treat conditions involving damaged tissue
, including corneal repair
, hepatic tissue injury
, inflammatory bowel disease
, and other tissue injury.
The Need
While MG53 is naturally present in skeletal and cardiac muscle, its levels are often insufficient to optimize tissue performance. Current treatments leveraging exogenous MG53 are therapeutically ineffective for conditions like multiple sclerosis, viral infections, radiation-induced tissue …
- College: College of Medicine (COM)
- Inventors: Ma, Jianjie; Tan, Tao; Zhu, Hua
- Licensing Officer: Schultz, Teri
Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College of Medicine (COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Willson, Christopher
Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 —
The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
- College: OSU Wexner Medical Center
- Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
- Licensing Officer: Willson, Christopher
A Breakthrough in Central Nervous System Repair
TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.
In the realm of central nervous system (CNS) repair, a critical need arises for innovative treatments that not only address the physical aspects of injury but also tackle the associated phychopathology. Understanding the cellular processes that occur after spinal cord injury (SCI) that are detrimen…
- College: College of Medicine (COM)
- Inventors: Tedeschi, Andrea
- Licensing Officer: Willson, Christopher
Show More Technologies
